{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:56:37Z","timestamp":1785884197370,"version":"3.56.0"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Ulcerative colitis (UC), one of the most stubborn diseases, is mainly treated by aminosalicylic acid (ASA). However, the side effects of ASA include vomiting, nausea, rash, diarrhea, headache, etc, which seriously affect life-quality of UC patients. Probiotics such as bifid triple viable (BTV) could reduce drug-induced adverse reactions and has a good clinical effect on UC. Therefore, we aimed to evaluate the clinical efficacy and safety of BTV plus ASA in treating UC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Cochrane Library, Embase, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, Chinese National Knowledge Infrastructure, and Wanfang databases were searched from the inception dates to October 12, 2018. Randomized controlled trials (RCTs) were included by comparing BTV plus ASA programs with ASA alone in patients with UC. Methodological quality was assessed by 2 independent researchers according to the inclusion criteria and exclusion criteria. Meta-analysis was performed by using the Review Manager 5.3 Software. Risk ratios (RRs), 95% confidence interval (CI), and standardized mean difference were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty RCTs involving 4954 participants were selected for final review. Compared with ASA, BTV plus ASA significantly improved the clinical effect rate [RR = 1.23, 95% CI (1.20, 1.26), <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001]; reduced the relapse rate [RR = 0.34, 95% CI (0.18, 0.62), <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0005]; and adverse effect rate [RR\u200a=\u200a0.66, 95% CI (0.53, 0.82), <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0002]. Compared with the controls, levels of tumor necrosis factor-\u03b1, interleukin-6 (IL-6), IL-8, C-reactive protein (CRP), hypersensitive CRP, erythrocyte sedimentation rate, and malondialdehyde were reduced; levels of IL-10, CD3+, CD4+, and superoxide dismutase were increased in BTV plus ASA group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>BTV plus ASA has positive therapeutic effects on UC, and it might be a safe way to treat UC. However, comprehensive clinical trials are needed to obtain high level of clinical evidence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017955","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:58:05Z","timestamp":1574665085000},"page":"e17955","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis"],"prefix":"10.1097","volume":"98","author":[{"given":"Mu-yuan","family":"Chen","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-wen","family":"Qiu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Tang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-hai","family":"Zhuang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qun","family":"Cai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-lin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-biao","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.dld.2018.08.016","article-title":"Epidemiology of inflammatory bowel disease in the Republic of San Marino: the\u201cEPIMICI-San Marino\u201d study","volume":"51","author":"Piscaglia","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjms.2018.06.023","article-title":"Use of curcumin in achieving clinical and endoscopic remission in ulcerative colitis: a systematic review and meta-analysis","volume":"356","author":"Iqbal","year":"2018","journal-title":"Am J Med Sci"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/ibd\/izy221","article-title":"An overview of molecular profiles in ulcerative colitis-related cancer","volume":"24","author":"Xue","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/1751-2980.12449","article-title":"The epidemiology of inflammatory bowel diseases from west to east","volume":"18","author":"Vegh","year":"2017","journal-title":"J Digest Dis"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41575-018-0003-z","article-title":"Urbanization and the gut microbiota in health and inflammatory bowel disease","volume":"15","author":"Zuo","year":"2018","journal-title":"Nat Rev Gastro Hepat"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharm Ther"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.3748\/wjg.v20.i16.4636","article-title":"Combined probiotic bacteria promotes intestinal epithelial barrier function in interleukin-10-gene-deficient mice","volume":"20","author":"Shi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3748\/wjg.v19.i5.742","article-title":"Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice","volume":"19","author":"Zhao","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/cas.13497","article-title":"Pretreatment of probiotic Bifico ameliorates colitis-associated cancer in mice: transcriptome and gut flora profiling","volume":"109","author":"Song","year":"2018","journal-title":"Cancer Sci"},{"key":"R11-20230915","first-page":"81","article-title":"Effect of mesalazine combined with bifid triple viable capsule on immune function and quality of life in patients with ulcerative colitis","volume":"50","author":"Qiao","year":"2018","journal-title":"Inner Mongolia Med J"},{"key":"R12-20230915","first-page":"1171","article-title":"Effects of Astragalus granules combined with probiotics on ulcerative colitis and its influence on IL-23 and IL-17","volume":"31","author":"Wang","year":"2016","journal-title":"Chin J Ctrl Endem Dis"},{"key":"R13-20230915","first-page":"41","article-title":"Effect of mesalazine combined with Bifico on immune function and inflammatory factors of ulcerative colitis patients","volume":"37","author":"Luo","year":"2017","journal-title":"Int J Dig Dis"},{"key":"R14-20230915","first-page":"47","article-title":"Clinical efficacy of mesalazine combined with Bifico in the treatment of ulcerative colitis","volume":"29","author":"Xu","year":"2017","journal-title":"Tianjin Phar"},{"key":"R15-20230915","first-page":"136","article-title":"Effects of mesalazine combined with Bifido on lipid peroxide level and inflammation factor level of ulcerative colitis patients","volume":"39","author":"Zhao","year":"2018","journal-title":"Jilin Med"},{"key":"R16-20230915","first-page":"43","article-title":"Effect of mesalazine combined with Bifico on ulcerative colitis and its influence on inflammatory factors","volume":"7","author":"Wang","year":"2017","journal-title":"Chin Med Pharm"},{"key":"R17-20230915","first-page":"114","article-title":"Efficacy of mesalazine combined with bifid triple viable capsule in treatment of ulcerative colitis and its influence on serum Hs-CRP, ESR, PLT, and D-dimer","volume":"14","author":"Zhao","year":"2017","journal-title":"Medica Innovation of China"},{"key":"R18-20230915","first-page":"2980","article-title":"Efficacy of mesalazine combined with Bifido in the treatment of colitis","volume":"28","author":"Mao","year":"2017","journal-title":"Mod Diagn Treat"},{"key":"R19-20230915","first-page":"43","article-title":"Analysis of effect of mesalazine combined with Bifido on ulcerative colitis","volume":"55","author":"Zhang","year":"2017","journal-title":"Chin Mod Doctor"},{"key":"R20-20230915","first-page":"1112","article-title":"Clinical efficacy of mesalazine combined with Bifico for treatment of ulcerative colitis: a Meta-analysis","volume":"39","author":"Han","year":"2017","journal-title":"Guangxi Med J"},{"key":"R21-20230915","first-page":"140","article-title":"Efficacy and safety of bifidobacterium triple viable bacteria combined with mesalazine for Chinese patients with inflammatory bowel disease: a meta-analysis","volume":"49","author":"Liao","year":"2018","journal-title":"J Shanxi Med Univer"},{"key":"R22-20230915","first-page":"919","article-title":"Live combined bifidobacterium, lactobacillus and enterococcus capsules\/powder in the treatment of ulcerative colitis: a meta-analysis","volume":"36","author":"Li","year":"2016","journal-title":"Chin J Pract Intern Med"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"e10807","DOI":"10.1097\/MD.0000000000010807","article-title":"Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jrsm.38","article-title":"Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3\/2011. Julian P.T. Higgins and Sally Green, Editors","volume":"2","author":"Shuster","year":"2011","journal-title":"Res Synth Methods"},{"key":"R25-20230915","first-page":"40","article-title":"Efficacy of Bifido in the treatment of ulcerative colitis","volume":"22","author":"Li","year":"2003","journal-title":"J Henan U Med Sci"},{"key":"R26-20230915","first-page":"114","article-title":"Clinical analysis of 154 cases of ulcerative colitis","volume":"15","author":"Xu","year":"2013","journal-title":"Chinese Community Doctors"},{"key":"R27-20230915","first-page":"461","article-title":"Analysis of therapeutic effect of combining mesalazine with Bifico in treatment of mild to moderate ulcerative colitis","volume":"28","author":"Wang","year":"2012","journal-title":"Pharm J Chin PLA"},{"key":"R29-20230915","first-page":"453","article-title":"Efficacy analysis of mesalazine granules combined with Bifico in the treatment of ulcerative colitis","volume":"11","author":"He","year":"2013","journal-title":"Guide China Med"},{"key":"R30-20230915","first-page":"98","article-title":"Efficacy analysis of mesalazine combined with Bifico in the treatment of ulcerative colitis","volume":"9","author":"Liu","year":"2012","journal-title":"World Health Digest Med"},{"key":"R31-20230915","first-page":"31","article-title":"Efficacy of mesalazine combined with Bifico in treatment of ulcerative colitis","volume":"53","author":"Xing","year":"2015","journal-title":"China Modern Doctor"},{"key":"R32-20230915","first-page":"18","article-title":"Observation of clinical effect of mesalazine combined with Bifico for patients with ulcerative colitis","volume":"32","author":"Deng","year":"2013","journal-title":"China & Foreign Medical Treatment"},{"key":"R33-20230915","first-page":"2565","article-title":"Study of mesalazine combined with Bifico in treatment of ulcerative colitis","volume":"23","author":"Yuan","year":"2007","journal-title":"Modern Med Health"},{"key":"R34-20230915","first-page":"498","article-title":"Effects of mesalazine combined with Bifico on TLR4 and MyD88 in the treatment of ulcerative colitis","volume":"16","author":"Zhang","year":"2014","journal-title":"J Chin Phys"},{"key":"R35-20230915","first-page":"42","article-title":"Clinical observation of mesalazine combined with bifid triple viable capsules in the treatment of ulcerative colitis","volume":"13","author":"Ding","year":"2015","journal-title":"J Commun Med"},{"key":"R37-20230915","first-page":"75","article-title":"Effect of combined therapy of mesalazine and probiotics in the treatment of ulcerative colitis","volume":"20","author":"Fan","year":"2013","journal-title":"China Modern Med"},{"key":"R38-20230915","first-page":"57","article-title":"Therapeutic effects of mesalazine combined with Bifico on ulcerative colitis and its influence on inflammation factors, stress protein and oxidative stress level","volume":"45","author":"Chen","year":"2016","journal-title":"J Med Res"},{"key":"R39-20230915","first-page":"133","article-title":"Analysis on the effect of Bifico combined with mesalazine in the treatment of ulcerative colitis","volume":"8","author":"Zhang","year":"2018","journal-title":"J Frontiers Med"},{"key":"R40-20230915","first-page":"2364","article-title":"Efficacy of Bifico combined with different drugs for the treatment of ulcerative colitis and its impact on NF-\u03baB and TNF-\u03b1","volume":"31","author":"Zhou","year":"2014","journal-title":"J Clin Res"},{"key":"R41-20230915","first-page":"138","article-title":"Effect of Bifico combined with mesalazine on inflammatory factors and immune function in patients with ulcerative colitis","volume":"38","author":"Wu","year":"2017","journal-title":"J Med Forum"},{"key":"R42-20230915","first-page":"228","article-title":"Clinical study of Bifico combined with mesalazine in the treatment of ulcerative colitis","volume":"4","author":"An","year":"2014","journal-title":"J Frontiers Med"},{"key":"R44-20230915","first-page":"272","article-title":"Analysis of the clinical effect of mesalazine combined with Bifico in the treatment of ulcerative colitis","author":"Wu","year":"2017","journal-title":"Health Guide"},{"key":"R45-20230915","first-page":"2192","article-title":"Effect of Bifico on inflammatory factors, oxidative stress and T lymphocyte subsets in patients with ulcerative colitis","volume":"23","author":"Lu","year":"2017","journal-title":"J Hainan Med Univ"},{"key":"R46-20230915","first-page":"100","article-title":"Effect of Bifido on serum D-lactic acid and diamine oxidase levels in patients with ulcerative colitis","volume":"31","author":"Chen","year":"2018","journal-title":"Med Equip"},{"key":"R47-20230915","first-page":"144","article-title":"Effect of bifid triple viable capsules combined with mesalazine on immune function and intestinal mucosal barrier function in patients with ulcerative colitis","volume":"38","author":"Feng","year":"2018","journal-title":"Int J Dig Dis"},{"key":"R48-20230915","first-page":"76","article-title":"Effect of bifid triple viable capsules combined with mesalazine on serum inflammatory cytokines and cyclooxygenase-2 in patients with ulcerative colitis","volume":"15","author":"Hu","year":"2018","journal-title":"Practical J Clin Med"},{"key":"R49-20230915","first-page":"696","article-title":"Evaluation of the efficacy of bifid triple viable capsules combined with mesalazine in the treatment of ulcerative colitis","volume":"31","author":"Zhang","year":"2014","journal-title":"J Clin Res"},{"key":"R50-20230915","first-page":"405","article-title":"Effect of Bifico combined with mesalazine on inflammatory factors, lipid peroxidation and coagulation function in patients with ulcerative colitis","volume":"19","author":"Ren","year":"2017","journal-title":"Zhejiang Clin Med J"},{"key":"R51-20230915","first-page":"51","article-title":"Analysis of the efficacy of bifid triple viable capsules combined with mesalazine granule in the treatment of ulcerative colitis","volume":"7","author":"Su","year":"2017","journal-title":"China Med Pharm"},{"key":"R52-20230915","first-page":"223","article-title":"Efficacy of bifid triple viable capsules combined with mesalazine in treatment of patients with ulcerative colitis","volume":"13","author":"Chen","year":"2014","journal-title":"Chin J Gen Pract"},{"key":"R53-20230915","first-page":"438","article-title":"Observation on the efficacy of Bifico combined with mesalazine in the treatment of mild-to-moderate ulcerative colitis","volume":"42","author":"Zhang","year":"2013","journal-title":"Shanxi Med J"},{"key":"R54-20230915","first-page":"1620","article-title":"Effect of bifid triple viable powder on inflammatory factors and T lymphocyte subsets in patients with ulcerative colitis","volume":"23","author":"Tang","year":"2017","journal-title":"J Hainan Med Univ"},{"key":"R55-20230915","first-page":"143","article-title":"Clinical effect of bifid triple viable powder combined with mesalazine enteric-coated tablets in the treatment of patients with ulcerative colitis","volume":"23","author":"Gao","year":"2016","journal-title":"China Modern Med"},{"key":"R56-20230915","first-page":"499","article-title":"Effect and safety of micro-ecological agent in the adjuvant treatment of mild-to-moderate ulcerative colitis","volume":"24","author":"Wang","year":"2017","journal-title":"Clin Med Eng"},{"key":"R57-20230915","first-page":"25","article-title":"Clinical observation of micro-ecological preparation combined with mesalazine in the treatment of 20 cases with ulcerative colitis","volume":"34","author":"Sun","year":"2013","journal-title":"Shanghai Med Pharm J"},{"key":"R58-20230915","first-page":"601","article-title":"Micro-ecological preparation combined with mesalazine in the treatment of mild-to-moderate ulcerative colitis and its influence on serum inflammatory factors","volume":"31","author":"Jia","year":"2017","journal-title":"Chin J School Doctor"},{"key":"R59-20230915","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.11569\/wcjd.v24.i17.2731","article-title":"Clinical efficacy of micro-ecological agents in treatment of mild-to-moderate ulcerative colitis","volume":"24","author":"Wang","year":"2016","journal-title":"World Chinese J Dige"},{"key":"R60-20230915","first-page":"38","article-title":"Effect of micro-ecological preparation on ulcerative colitis","volume":"38","author":"Zhang","year":"2017","journal-title":"J Mudanjiang Med Univ"},{"key":"R61-20230915","first-page":"102","article-title":"Effect of probiotics on mild-to-moderate ulcerative colitis in active stage","volume":"25","author":"Gong","year":"2015","journal-title":"China Health Care Nutr"},{"key":"R62-20230915","first-page":"2228","article-title":"Clinical observation of probiotics combined with mesalazine in the treatment of ulcerative colitis","volume":"31","author":"Liu","year":"2010","journal-title":"Jilin Med J"},{"key":"R63-20230915","first-page":"4303","article-title":"Observation on the effect of probiotics combined with mesalazine in the treatment of ulcerative colitis","volume":"26","author":"Li","year":"2017","journal-title":"Henan Med Res"},{"key":"R65-20230915","doi-asserted-by":"crossref","first-page":"404752","DOI":"10.1155\/2012\/404752","article-title":"The effect of bifid triple viable on immune function of patients with ulcerative colitis","volume":"2012","author":"Li","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"R66-20230915","first-page":"61","article-title":"Study on the clinical effects of sulfasalazine combined with Bifico in patients with ulcerative colitis","volume":"28","author":"Shi","year":"2007","journal-title":"J Tongji U Med Sci"},{"key":"R67-20230915","first-page":"265","article-title":"The effect of sulfasalazine combined with bifid triple viable capsules on mild-to-moderate ulcerative colitis","volume":"28","author":"Jiang","year":"2015","journal-title":"Med Inform"},{"key":"R68-20230915","first-page":"783","article-title":"Clinical effects of sulfasalazine combined with bifid triple viable capsules in patients with ulcerative colitis","volume":"29","author":"Shi","year":"2010","journal-title":"Chin J New Drugs Clin Rem"},{"key":"R69-20230915","first-page":"585","article-title":"The effect of Bifico on serum IL-18 and IL-4 of patients with mild-to-moderate ulcerative colitis","volume":"26","author":"Tian","year":"2010","journal-title":"Occup Health"},{"key":"R70-20230915","first-page":"668","article-title":"Therapeutic effect of Bifico combined with sulfasalazine on T lymphocyte subsets and inflammatory factors in ulcerative colitis","volume":"29","author":"Xie","year":"2016","journal-title":"Heilongjiang Med J"},{"key":"R71-20230915","first-page":"542","article-title":"Clinical observation of Bifico combined with sulfasalazine in the treatment of ulcerative colitis","volume":"32","author":"Zhu","year":"2011","journal-title":"Shanghai Med Pharm J"},{"key":"R72-20230915","first-page":"191","article-title":"Clinical observation of bifid triple viable capsules combined with sulfasalazine in the treatment of ulcerative colitis","volume":"17","author":"Hong","year":"2010","journal-title":"Chin J Prim Med Pharm"},{"key":"R73-20230915","first-page":"121","article-title":"Clinical efficacy of Bifico combined with olsalazine in the treatment of ulcerative colitis and the effect on mucosal lesions under endoscope","volume":"17","author":"Huang","year":"2014","journal-title":"Pract Pharm Clin Remed"},{"key":"R74-20230915","first-page":"932","article-title":"Clinical effect of Bifico combined olsalazine in treating ulcerative colitis","volume":"33","author":"Liu","year":"2009","journal-title":"Heilongjiang Med J"},{"key":"R75-20230915","first-page":"55","article-title":"Clinical observation of Bifico combined with olsalazine in the treatment of ulcerative colitis","volume":"48","author":"Wei","year":"2010","journal-title":"China Modern Doctor"},{"key":"R76-20230915","doi-asserted-by":"crossref","first-page":"17278","DOI":"10.1038\/s41598-018-35243-4","article-title":"The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients","volume":"8","author":"Moen","year":"2018","journal-title":"Sci Rep"},{"key":"R77-20230915","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MPG.0000000000002140","article-title":"Enteric virome and bacterial microbiota in children with ulcerative colitis and Crohn's disease","volume":"68","author":"Fernandes","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R78-20230915","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.intimp.2018.04.014","article-title":"Fecal microbiome from patients with ulcerative colitis is potent to induce inflammatory responses","volume":"59","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"R79-20230915","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/MCG.0000000000000368","article-title":"Probiotics in the management of ulcerative colitis","volume":"49","author":"Chibbar","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"R80-20230915","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.14203","article-title":"Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease","volume":"46","author":"Derwa","year":"2017","journal-title":"Aliment Pharm Ther"},{"key":"R82-20230915","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/11632710-000000000-00000","article-title":"Probiotics in the management of inflammatory bowel disease","volume":"72","author":"Jonkers","year":"2012","journal-title":"Drugs"},{"key":"R83-20230915","first-page":"3466","article-title":"Meta analysis of clinical effect of probiotics combined with mesalazine on inflammatory bowel disease","volume":"26","author":"Li","year":"2017","journal-title":"Henan Med Res"},{"key":"R84-20230915","first-page":"4","article-title":"Meta analysis of effect of probiotic on remission and maintenance treatment in active ulcerative colitis","volume":"22","author":"Zhang","year":"2016","journal-title":"Cont Med"},{"key":"R85-20230915","first-page":"BSR20180943","article-title":"Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial","volume":"9","author":"Peng","year":"2018","journal-title":"Biosci Rep"},{"key":"R86-20230915","first-page":"1399","article-title":"Meta-analysis of combined living Bacillus subtilis and Enterococcus faecium enteric-coated capsules plus mesalazine in treating ulcerative colitis","volume":"38","author":"Chen","year":"2018","journal-title":"Chin Hosp Pharm J"},{"key":"R87-20230915","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12876-016-0470-z","article-title":"Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"R88-20230915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3920\/BM2016.0140","article-title":"A review of dose-responses of probiotics in human studies","volume":"8","author":"Ouwehand","year":"2017","journal-title":"Benef Microbes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:09:11Z","timestamp":1694815751000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017955"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":83,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017955","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}